BNTX
BioNTech SE
96.90$
-1.5%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 18.1% | 12.1% | 31.5% | 46.5% | 14.4% | 20.5% | 45.8% | 29.3% | 9.8% | 36.7% | 163.2% | 91.9% | 29.2% | |
| 81.9% | 87.9% | 68.5% | 53.5% | 85.6% | 79.5% | 54.2% | 70.7% | 90.2% | 63.3% | -63.2% | 8.1% | 70.8% | |
| 55.6% | 39.1% | 270.5% | 454.2% | 44.2% | 51.4% | 287.5% | 195.2% | 37.2% | 55.7% | 471.6% | 521.8% | 82.6% | |
| 15.5% | 8.9% | 62.4% | 132.8% | 10.6% | 9.3% | 58.5% | 45.1% | 8.0% | 27.0% | 102.4% | 149.3% | 24.4% | |
| 73.8% | 52.3% | 338.9% | 804.3% | 84.8% | 67.1% | 346.3% | 262.8% | 93.3% | 88.9% | 496.6% | 906.0% | 142.6% | |
| 8.2% | 35.6% | -270.4% | -750.7% | 0.8% | 12.5% | -292.2% | -192.1% | -3.1% | -25.7% | -559.8% | -897.8% | -71.8% | |
| 0.2% | 1.3% | 2.5% | 5.7% | 0.4% | 0.6% | 3.4% | 1.3% | 0.0% | 0.7% | 3.4% | 7.5% | 0.7% | |
| 25.4% | 44.8% | -176.9% | -626.1% | 12.7% | 25.3% | -243.7% | -154.4% | 1.6% | -25.1% | -481.0% | -813.2% | -61.9% | |
| 7.5% | 13.9% | -8.9% | 1.6% | -3.2% | 3.5% | -16.2% | -6.2% | 3.5% | 8.6% | -30.7% | -35.9% | 2.1% | |
| 17.9% | 31.0% | -168.0% | -627.7% | 15.9% | 21.8% | -227.5% | -148.2% | -1.9% | -33.6% | -450.4% | -777.3% | -64.0% | |
| 30.2% | 30.8% | -153.9% | -584.7% | 17.0% | 39.0% | -201.7% | -133.6% | 9.8% | -6.2% | -374.9% | -553.7% | -35.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.